Grizzly Research short GeneDx, says ‘actively committing widespread fraud’
Grizzly Research is short GeneDx (WGS), saying insiders attest that the company is “actively committing widespread fraud.” In a recently ...
GeneDx down 3% after Grizzly Research publishes short report, alleging fraud
EST GeneDx (WGS) down 3% after Grizzly Research publishes short report, alleging fraudMaximize Your Portfolio with Data Driven ...
Investing on MSN6d
GeneDx targeted in short report by Grizzly Research
In 2022, before changing its name from Sema4 to GeneDx, the company had a dispute with UnitedHealthcare, which resulted in a ...
Investing6d
GeneDx targeted in short report by Grizzly Research
Investing.com -- Grizzly Research has shorted GeneDx, a genetic testing company, accusing them of widespread fraud. GeneDx specializes in advanced genomic testing, with a focus on rare and ultra ...
GeneDx drops after short report; Wall Street analysts defend (update)
Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).
Investing6d
GeneDx stock holds steady despite fraud allegations
BTIG analysts have maintained a Buy rating for GeneDx, despite a short report from Grizzly Research accusing the company of fraudulent practices. Analysts from TD Cowen also expressed confidence in ...